United Therapeutics Corp
UTHR: XNAS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$914.00 | Ltvx | Bxxrvhpd |
United Therapeutics Earnings: Robust Growth Thanks to Strong Tyvaso DPI Sales; Shares Fairly Valued
United Therapeutics reported robust second-quarter results highlighted by revenue of $597 million, representing growth of 28% year over year. Tyvaso DPI, which is a dry powder inhaler for the treatment of pulmonary arterial hypertension, was launched in June 2022 and has seen strong patient demand. We raised our fair value estimate to $221 per share from $213, primarily due to the time value of money since our last update. We view shares as fairly valued, currently trading in 3-star territory.